Merck and Kelun-Biotech ADC drug reduces risk of death in advanced endometrial cancer
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
A randomized Phase 3 study presented Monday in Madrid shows that sacituzumab tirumotecan (sac-TMT), developed by Merck and China's Kelun-Biotech, cut the risk of death by one-third for patients with advanced endometrial cancer. Merck is conducting 18 global Phase 3 studies of the drug to support approvals outside China.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu